Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data reveals immunotherapy Combo's impact on esophageal cancer

NCT ID NCT05142709

Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study analyzed medical records from 1197 patients in China with advanced esophageal cancer who received immunotherapy (anti-PD-1) plus chemotherapy as their first treatment. The goal was to see how long patients lived and how long the cancer stayed under control in everyday medical practice, not just in a controlled trial. The results help doctors understand the real-world benefits of this combination therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,197 people

The number who actually took part.

Started

Oct 2021

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

More than 600 patients

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age \> 18, had an Eastern Cooperative Oncology Group performance status score of 0-3; Patients had unresectable or recurrent disease that precluded esophagectomy or definitive chemoradiation, or distant metastatic disease; Patients had received no previous systemic therapy (patients who had progressed ≥6 months after \[neo\]adjuvant therapy or definitive chemoradiation were eligible); Patients accepted at least one cycle of anti-PD-1 immunotherapy as 1st line treatment, combined chemotherapy was allowed. Patients who provided informed consent by appropriate methods. In dead case, optout will be applicable. Exclusion Criteria: Patients who are prior exposure to immune-mediated therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic esophageal squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic esophageal squamous cell carcinoma

Contacts and locations

Locations

  • Anyang cancer hospital

    Anyang, Henan, China

  • Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center

    Shenzhen, Guangdong, China

  • Fudan University Shanghai cancer center

    Shanghai, Shanghai Municipality, 200032, China

  • Fujian Cancer Hospital & Fujian Medical University Cancer Hospital

    Fuzhou, Fujian, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Huai'an first hospital

    Huai'an, Jiangsu, China

  • Jiangsu cancer Hosipital

    Nanjing, Jiangsu, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China

  • Nantong cancer hospital

    Nantong, Jiangsu, China

  • Sichuan cancer hospital

    Chengdu, Sichuan, China

  • The 1st affiliated hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The 1st affiliated hospital of Xiamen University

    Xiamen, Fujian, China

  • The 2nd affiliated hospital of Bengbu medical University

    Bengbu, Anhui, China

  • The 2nd affiliated hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The 2nd affiliated hospital of Wenzhou medical university

    Wenzhou, Zhejiang, China

  • The 2nd people's hospital of Anhui province

    Hefei, Anhui, China

  • The 4th affiliated hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The First Affiliated Hospital of Air Force Medical University

    Xi'an, Shaanxi, China

  • The Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • Wuhan University Zhongnan hospital

    Wuhan, Hubei, China

  • Yancheng the 3rd hospital

    Yancheng, Jiangsu, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • Zhongnan University Xiangya Hospital

    Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.